| Arthritis, Psoriatic
Remicade vs Rayos
Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.Deep comparison between: Remicade vs Rayos with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRayos has a higher rate of injection site reactions vs Remicade based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rayos but not Remicade, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Remicade
Rayos
At A Glance
IV infusion
Every 8 weeks
TNF-alpha inhibitor
Oral
Daily
Corticosteroid
Indications
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
Dosing
Crohn Disease, Ulcerative Colitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks (adults and pediatric patients >= 6 years).
Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; dose may be increased up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete responders.
Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks.
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Contraindications
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab, any inactive ingredient of REMICADE, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)
- Known hypersensitivity to prednisone or any excipient
Adverse Reactions
Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain.
Serious Pneumonia, cellulitis, abscess, sepsis, bacterial infection, hepatotoxicity, acute liver failure, malignancies (including lymphoma), pancytopenia, thrombocytopenia, leukopenia.
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction.
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Pharmacology
TNF-alpha antagonist; infliximab is a chimeric IgG1 monoclonal antibody that neutralizes the biological activity of TNF-alpha by binding with high affinity to both soluble and transmembrane forms of TNF-alpha and inhibiting its binding to receptors, thereby reducing inflammation in RA, CD, UC, AS, PsA, and Ps.
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Remicade
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (0/12)
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Remicade
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Remicade
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Remicade.
No savings programs available for Rayos.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RemicadeView full Remicade profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.